FDA Brief

Warning letters Drugs

FDA warning letter to

Froggy’s Fog LLC

High riskIssued Apr 14, 2022Posted May 3, 2022Office of Pharmaceutical Quality Operations, Division II

FDA warns Froggy’s Fog that its OTC hand sanitizer was made under inadequate CGMP and mislabeled for alcohol strength.

What happened

FDA inspected Froggy’s Fog’s drug manufacturing facility on September 15, 2021 and found missing process and water validation, inadequate finished-product and incoming-material testing, and unvalidated cleaning for shared equipment. FDA laboratory testing of SIMPLY 70 HAND SANITIZER GEL found ethanol at an average of 61% v/v, or about 60% v/v in the misbranding section, versus the 70% label claim.

What FDA found

  1. The firm lacked written production and process controls and could not provide adequate process or water system validation.

    21 CFR 211.100(a)
  2. The firm did not adequately test each batch before release for identity, strength, impurities, and microorganisms, and its density meter was unsuitable for finished hand sanitizer strength testing.

    21 CFR 211.165(a) and 21 CFR 211.165(b)
  3. The firm’s analytical test methods, including for ethanol, were not adequately validated.

    21 CFR 211.160(b)
  4. The firm did not adequately test incoming components for identity or establish supplier certificate-of-analysis reliability, did not test ethanol for methanol, and did not test glycerin for diethylene glycol.

    21 CFR 211.84(d)(1) and (2)
  5. The firm did not establish and follow adequate cleaning and maintenance procedures, and did not validate cleaning for non-dedicated equipment shared with non-pharmaceutical products.

    21 CFR 211.67(b)
  6. SIMPLY 70 HAND SANITIZER GEL was misbranded because its label said 70% alcohol while FDA testing found about 60% to 61% ethanol.

    FD&C Act section 502(a), 21 U.S.C. 352(a)

What FDA wants

FDA tells Froggy’s Fog to correct the violations promptly and respond in writing within 15 working days with corrective actions or a reason for delay and a completion schedule. FDA also asks for validation, testing, supplier qualification, cleaning, and risk-assessment plans.

Who should pay attention

  • companies that buy or distribute OTC hand sanitizer
  • contract manufacturers and labs testing hand sanitizer
  • quality teams managing shared equipment and supplier certificates

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk